Bloomgarden in Journal of Diabetes: "Beyond GLP-1" — Tolerability Ceilings and Non-Responder Limits Drive the Next Wave
Bloomgarden's commentary in the Journal of Diabetes (2026, vol 18, e70204) frames the clinical case for moving past first-generation GLP-1 agonists, focusing on two limits: gastrointestinal intolerance that forces dose reduction or discontinuation in 15-30% of patients depending on agent and titration, and a non-responder problem where roughly 10-20% of treated individuals fail to reach the expected weight-loss range. With 12% of US adults reported to have at least temporarily received a GLP-1 agonist, the population-level stakes are large. The commentary lands alongside the Frontiers Drug Discovery 'Beyond GLP-1' review as one of two academic pieces this month formalizing the post-incretin research agenda — and aligns with the AstraZeneca ASCEND triple-mechanism thesis, the petrelintide + enicepatide combination program, and Lilly's quintuple agonist disclosed for ADA 2026.